JCI Insight (2020)
Given the clinical evidence reviewed above, patients with type 2 diabetes and/or obesity are the most promising candidate population to benefit from GLP-1RA-centered pharmacotherapy to improve cardiovascular and kidney outcomes
ArGLP-1 also reduced total mortality (HR 0.88, 95% CI 0.820.94, p = 0.0001) and hospital admission due to heart failure (HR 0.89, 95% CI 0.820.98, p = 0.013), all without increasing the risk of severe hypoglycemia, pancreatic problems or retinopathy.87 A recent post hoc analysis of CVOT with semaglutide has shown a gain in time free of cardiovascular disease of 1.7 years in those patients with CKD vs
Common side effects include nausea, decreased appetite (which can aid in weight loss), and occasional mild constipation, diarrhea, or stomach discomfort
Harder stools Increased bloating More abdominal discomfort Feeling overly full after eating Less frequent bowel motions Some people do perfectly well on GLP-1s with the right support, but others find constipation becomes significantly worse especially if hydration, food intake or fibre balance arent carefully managed
